Results 1 to 10 of about 16,901 (99)

Radiolabeled Silicon-Rhodamines as Bimodal PET/SPECT-NIR Imaging Agents

Pharmaceuticals, 2021
Radiolabeled fluorescent dyes are decisive for bimodal imaging as well as highly in demand for nuclear- and optical imaging. Silicon-rhodamines (SiRs) show unique near-infrared (NIR) optical properties, large quantum yields and extinction coefficients as
Thines Kanagasundaram, Markus Laube, Johanna Wodtke, Carsten Sven Kramer, Sven Stadlbauer, Jens Pietzsch, Klaus Kopka   +6 more
doaj   +1 more source

CRISPR/Cas9 Mediated Knockout of Cyclooxygenase-2 Gene Inhibits Invasiveness in A2058 Melanoma Cells

Cells, 2022
The inducible isoenzyme cyclooxygenase-2 (COX-2) is an important hub in cellular signaling, which contributes to tumor progression by modulating and enhancing a pro-inflammatory tumor microenvironment, tumor growth, apoptosis resistance, angiogenesis and
Cathleen Haase-Kohn, Markus Laube, Cornelius K. Donat, Birgit Belter, Jens Pietzsch   +4 more
doaj   +1 more source

Synthesis of [18F]FMISO, a hypoxia-specific imaging probe for PET, an overview from a radiochemist’s perspective

EJNMMI Radiopharmacy and Chemistry, 2023
Background [18F]fluoromisonidazole ([18F]FMISO, 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole) is a commonly used radiotracer for imaging hypoxic conditions in cells.
Torsten Kniess, Jörg Zessin, Peter Mäding, Manuela Kuchar, Oliver Kiss, Klaus Kopka   +5 more
doaj   +1 more source

Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells

Molecules, 2022
COX-2 can be considered as a clinically relevant molecular target for adjuvant, in particular radiosensitizing treatments. In this regard, using selective COX-2 inhibitors, e.g., in combination with radiotherapy or endoradiotherapy, represents an ...
Florian Brandt, Martin Ullrich, Verena Seifert, Cathleen Haase-Kohn, Susan Richter, Torsten Kniess, Jens Pietzsch, Markus Laube   +7 more
doaj   +1 more source

Prediction of radiation dose to adult human from radiopharmaceutical manufactured by third generation bisphosphonate labeled with Rhenium

Nuclear Engineering and Technology, 2023
Introduction: The crucial step in preclinical process of radiopharmaceutical production is internal dosimetry evaluation by different ways to realize radiobiological dose-response relationships and to extract the results for clinical use.
Zahra Pourhabib, Hassan Ranjbar
doaj   +1 more source

Fluorination of silyl prosthetic groups by fluorine mediated silyl ether linker cleavage: a concept study with conditions applicable in radiofluorination

EJNMMI Radiopharmacy and Chemistry, 2022
Background Positron emission tomography (PET) is a powerful tool in medical imaging, especially in combination with the PET radionuclide fluorine-18 that possesses optimal characteristics.
Carsten Sven Kramer, Luca Greiner, Klaus Kopka, Martin Schäfer   +3 more
doaj   +1 more source

Sulfur [¹⁸F]Fluoride Exchange Reaction Enables Rapid Access to ¹⁸F-Labeled PET Tracers

Medical Sciences Forum, 2022
Efficient 18F-fluorination procedures for the production of radiopharmaceuticals are urgently needed to satisfy the increasing demand for clinical diagnostics using positron emission tomography (PET).
Austin Craig, Jürgen Kogler, Fabian Krutzek, Florian Brandt, Markus Laube, Martin Ullrich, Cornelius Kurt Donat, Klaus Kopka, Sven Stadlbauer   +8 more
doaj   +1 more source

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy

OncoImmunology, 2020
Chimeric antigen receptor (CAR) T cells show remarkable therapeutic effects in some hematological malignancies. However, CAR T cells can also cause life-threatening side effects.
Anja Feldmann, Anja Hoffmann, Ralf Bergmann, Stefanie Koristka, Nicole Berndt, Claudia Arndt, Liliana Rodrigues Loureiro, Enrico Kittel-Boselli, Nicola Mitwasi, Alexandra Kegler, Chris Lamprecht, Karla Elizabeth González Soto, Michael Bachmann   +12 more
doaj   +1 more source

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source

Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files

Frontiers in Oncology, 2019
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity.
Charles A. Kunos, Jacek Capala, Susan Percy Ivy   +2 more
doaj   +1 more source